Concept of the vulnerable parameter: the Sicilian Gambit revisited.
Why consider the concept of the vulnerable parameter in a series on "Noninvasive Risk Assessment in Guiding Therapy for Prevention of Sudden Death?" Preceding that question might be, "what is the vulnerable parameter?" In the following pages, we shall review the history behind the concept of the vulnerable parameter, its evolution after its initial identification, where it stands today, and finally, why the vulnerable parameter is important to our consideration of risk factors.
Rosen
Michael R
MR
Center for Molecular Therapeutics, Department of Pharmacology and Pediatrics, and Pediatrics, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA. mrr1@columbia.edu
Janse
Michiel J
MJ
D000200:Action Potentials / Q000187:drug effects; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D016757:Death, Sudden, Cardiac / Q000209:etiology* / Q000517:prevention & control*; D015195:Drug Design; D006801:Humans; D007473:Ion Channels / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D018570:Risk Assessment
D000889:Anti-Arrhythmia Agents; D007473:Ion Channels